<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1093">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146921</url>
  </required_header>
  <id_info>
    <org_study_id>KCH19-085</org_study_id>
    <nct_id>NCT05146921</nct_id>
  </id_info>
  <brief_title>Gut Health and Probiotics in Parkinson's (SymPD)</brief_title>
  <official_title>Gut Health and Probiotics in Parkinson's (SymPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College Hospital NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current literature suggests that the gut microbiota is altered in patients with Parkinson's&#xD;
      disease (PD) and might play a role in the clinical presentation and pathogenesis of this&#xD;
      condition. The latter has driven the interest in investigating the use of gut&#xD;
      microbiota-modulating interventions, such as probiotics, as possible novel therapeutic&#xD;
      strategies for PD. Symprove is a food supplement working as an oral active probiotic which&#xD;
      unlike many commercially available probiotics can reach the intestine and has been shown to&#xD;
      be beneficial for gut health in gastrointestinal disorders.To date, no research has explored&#xD;
      the possible effects of the intake of Symprove in PD. This is an exploratory study with a&#xD;
      randomised, double-blind, placebo-controlled design investigating the effects of a 12-week&#xD;
      probiotic intervention (Symprove) on gut and general health in 60 patients with PD and&#xD;
      constipation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2019</start_date>
  <completion_date type="Anticipated">July 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gut microbiota of study population</measure>
    <time_frame>Baseline</time_frame>
    <description>Gut microbiota will be evaluated with shallow shotgun sequencing of stool samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of gut microbiota following probiotic intervention and their association with changes in Parkinson's symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Gut microbiota changes will be evaluated with shallow shotgun sequencing of stool samples while Parkinson's symptoms changes will be evaluated with subjective and objective measurements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in blood levels of inflammatory markers (i.e. C-reactive protein, cytokines, tight junction proteins, and short-chain fatty acids levels)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>food supplement: multi-strain probiotic (Symprove)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>70 ml daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>70 ml daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multi-strain probiotic</intervention_name>
    <description>The intervention in this study is a multi-strain probiotic which contains four live strains of bacteria:&#xD;
Lacticaseibacillus rhamnosus NCIMB 30174 Enterococcus faecium NCIMB 30176 Lactobacillus acidophilus NCIMB 30175 Lactiplantibacillus plantarum NCIMB 30173&#xD;
10 billion colony-forming units (CFU) per 70 ml cup</description>
    <arm_group_label>food supplement: multi-strain probiotic (Symprove)</arm_group_label>
    <other_name>Symprove</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo similar in appearance and taste to the active intervention but with no active bacteria</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 18 and upwards&#xD;
&#xD;
          -  Diagnosis of idiopathic Parkinson's disease according to the Movement Disorder Society&#xD;
             clinical diagnostic criteria&#xD;
&#xD;
          -  Hoehn Yarh stage II-IV&#xD;
&#xD;
          -  Diagnosis of constipation according to the ROME IV criteria and â‰¤ than 3 complete&#xD;
             bowel movements per week&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis or suspicion of other causes for parkinsonism&#xD;
&#xD;
          -  Advanced-stage therapies (deep brain stimulation, intrajejunal levodopa infusion, and&#xD;
             apomorphine subcutaneous infusion)&#xD;
&#xD;
          -  Any inflammatory bowel disease or diseases of the colon&#xD;
&#xD;
          -  Previous surgery on the gastrointestinal tract&#xD;
&#xD;
          -  History of laxative abuse&#xD;
&#xD;
          -  Ongoing artificial nutrition&#xD;
&#xD;
          -  Regular use of probiotics&#xD;
&#xD;
          -  Previous intolerance and/or adverse reactions to probiotics&#xD;
&#xD;
          -  Previous use of Symprove&#xD;
&#xD;
          -  Recent or current use of any antibiotics (within 4 weeks before the start of the&#xD;
             study)&#xD;
&#xD;
          -  Swallowing issues interfering with the safety intake of the probiotic/placebo&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Major systemic disease&#xD;
&#xD;
          -  Any condition interfering with the ability to give the informed consent&#xD;
&#xD;
          -  Enrolment in another simultaneous investigational trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K Ray Chaudhuri, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valentina Leta, MD</last_name>
    <phone>02032997189</phone>
    <email>valentina.leta@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Leta, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Pavlos Zinzalias, MSc</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

